Joseph T. Baroldi - 15 Jan 2025 Form 4 Insider Report for IONIS PHARMACEUTICALS INC (IONS)

Role: EVP, Chief Business Officer
Signature: By: Patrick R. O'Neil, attorney-in-fact For: Joseph T. Baroldi
Issuer symbol: IONS
Transactions as of: 15 Jan 2025
Net transactions value: -$144,861
Form type: 4
Filing time: 17 Jan 2025, 19:40:01 UTC
Previous filing: 06 Jan 2025
Next filing: 17 Apr 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	IONS	Common Stock	Options Exercise	$0	+8,787	+45%	$0.000000	28,418	15 Jan 2025	Direct	F1
transaction	IONS	Common Stock	Sale	$111,213	-3,401	-12%	$32.70	25,017	16 Jan 2025	Direct	F2
transaction	IONS	Common Stock	Options Exercise	$0	+2,460	+150%	$0.000000	4,100	15 Jan 2025	by Spouse	F1
transaction	IONS	Common Stock	Sale	$33,648	-1,029	-25%	$32.70	3,071	16 Jan 2025	by Spouse	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	IONS	Performance Restricted Stock Units	Award	$0	+22,000	+75%	$0.000000	51,290	15 Jan 2025	Common Stock	22,000	$0.000000	Direct	F3, F4
transaction	IONS	Restricted Stock Unit	Award	$0	+33,000	+62%	$0.000000	86,135	15 Jan 2025	Common Stock	33,000	$0.000000	Direct	F5, F6, F7
transaction	IONS	Restricted Stock Unit	Options Exercise	$0	-8,787	-10%	$0.000000	77,348	15 Jan 2025	Common Stock	8,787	$0.000000	Direct	F6, F7
transaction	IONS	Restricted Stock Unit	Award	$0	+3,750	+53%	$0.000000	10,784	15 Jan 2025	Common Stock	3,750	$0.000000	by Spouse	F6, F7, F8
transaction	IONS	Restricted Stock Unit	Options Exercise	$0	-2,460	-23%	$0.000000	8,324	15 Jan 2025	Common Stock	2,460	$0.000000	by Spouse	F6, F7

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.
F2	The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.
F3	Grant to reporting person of Performance Restricted Stock Units (PRSUs) under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.
F4	The PRSUs may vest at the end of the three-year performance period following the date of grant based on the Issuer's relative total shareholder return as compared to a peer group of companies. The number of PRSUs reported represents the maximum that may be earned, which is 200% of the target number. No number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of the performance period may be anywhere from zero to the amount stated.
F5	Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.
F6	Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.
F7	Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.
F8	Grant to reporting person's spouse of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.